Pfizer stays in the autism drug chase

After a period of silence that followed its much-touted efforts in autism research a few years ago, Pfizer ($PFE) appears to be in the hunt to develop drugs that could address symptoms of the brain disorder. In a mouse study, the drug giant's experimental depression drug GRN-529 reduced visible signs of autism in mice, Bloomberg reported. Pfizer plans further study of the drug after the findings, which were published in Science Translational Medicine. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.